A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)

NCT ID: NCT00779129

Last Updated: 2015-09-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-03-31
• Study Completion Date: 2007-08-31

Brief Summary

Women with metastatic breast cancer are usually treated with anthracyclines (ie, doxorubicin or epirubicin) but cardiac toxicity limits their use. The aim of this study is to evaluate the safety and efficacy of Caelyx in combination with cyclophosphamide in women with metastatic breast cancer who have received adjuvant anthracyclines with or without a taxane.

Conditions

Breast Neoplasm

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single Arm

Caelyx 35 mg/m2 and Cyclophosphamide 600 mg/m2

Group Type: EXPERIMENTAL

Pegylated Lyposomal Doxorubicin

Intervention Type: DRUG

Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.

Cyclophosphamide

Intervention Type: DRUG

Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.

Interventions

Pegylated Lyposomal Doxorubicin

Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.

Intervention Type: DRUG

Cyclophosphamide

Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.

Intervention Type: DRUG

Other Intervention Names

SCH 200746

Eligibility Criteria

Inclusion Criteria

• Female, aged >=18 years.
• Subject must have histologic diagnosis of breast carcinoma.
• Subject must have documented measurable metastatic breast cancer by appropriate radiologic imaging.
• Subject must have previous anthracyclin-based adjuvant regimen and disease-free status for at least one year following the completion of adjuvant therapy.
• Subject must have ECOG performance status 0, 1, or 2.
• Subject must have life expectancy > 6 months
• Subject must have left ventricular ejection fraction >=55% as determined by MUGA scan.
• Subject must have normal organ function, except if abnormal due to tumor involvement:

• Adequate bone marrow function (platelets >=100 X 10^9/L, hemoglobin >=90 g/L, Neutrophils >=1.5 X 10^9/L)
• Adequate renal function (serum creatinine < 2 X the upper limit of normal (ULN)
• Adequate liver function (bilirubin < 2 times ULN, AST or ALT < 2 times ULN in the absence of liver metastasis, AST or ALT < 5 times ULN in the presence of liver metastasis.
• Women of childbearing potential must be using adequate contraception and have a negative pregnancy test at the time of enrollment.
• Subject must be able to understand and give informed consent.

Exclusion Criteria

• Age > 75 years old.
• Subject who is pregnant or breastfeeding or is unwilling to use adequate contraception.
• Subject who has had a previous chemotherapy for metastatic disease.
• Subject who has history of cardiac disease, with New York Heart Association Class II or greater with congestive heart failure.
• Subject who has clinically significant hepatic disease in regard to Hepatitis B, Hepatitis C, cirrhosis, or other liver diseases unrelated to the underlying metastatic breast cancer.
• Subject who has uncontrolled bacterial, viral, or fungal infection.
• Subject who exhibits confusion or disorientation.
• Subject with any condition which would prevent adequate follow-up.
• Subject who has received radiotherapy in the last 4 weeks.
• Subject with any other active primary tumor under treatment, except basal cell carcinoma of the skin, or carcinoma in situ of the cervix.
• Subject who has brain metastasis.
• Subject who is not able to give informed consent.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Princess Margaret Hospital, Canada

OTHER

Sponsor Role: collaborator

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

References

Trudeau ME, Clemons MJ, Provencher L, Panasci L, Yelle L, Rayson D, Latreille J, Vandenberg T, Goel R, Zibdawi L, Rahim Y, Pouliot JF. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. J Clin Oncol. 2009 Dec 10;27(35):5906-10. doi: 10.1200/JCO.2009.22.7504. Epub 2009 Oct 26.

Reference Type: RESULT

PMID: 19858391 (View on PubMed)

Other Identifiers

P02948

Identifier Type: -

Identifier Source: org_study_id